DMARD exposure overall during pregnancy is not associated with severe maternal or neonatal morbidity, in this Ontario cohort. We’re getting better at finding a balance with DMARDs that is safe for both mother and baby. Blanket resistance is harmful #ACR25 ABST2627 @RheumNow https://t.co/oDOpySGS3N

• https://x.com/drdavidliew/status/1983266245169561651/photo/1

Large Canada ICES dataset- DMARD use is not associated with adverse pregnancy outcomes. In pts with RA, SlE and other rheumatic diseases. Abst#2627 #ACR25 @RheumNow https://t.co/T9Ll1FNjT7

• https://x.com/bella_mehta/status/1983266032837156870/photo/1
• https://x.com/bella_mehta/status/1983266032837156870/photo/1

Predictors of retinopathy progression after HCQ discontinued? In the chart review of 28 pt records who had retinopathy, 35% progressed despite d/c Age - significant assoc'n with progression ✳️monitor toxicity more closely esp in older pts #ACR25 @RheumNow Abs2444 https://t.co/9rf2RQAgRQ

• https://x.com/RHEUMarampa/status/1983262824530096270/photo/1

A new IA drug in OA 🚨 Cell therapy of apoptotic PBMCs ENX-CL-05-001 RCT Ph2A moderate to severe OA 134 pts 3 injections vs. PBO Pain improvement 24% Better response in people > 60 and more so 65yo Potential improvement for > 6mo Safety mainly local reactions to compound https://t.co/m2MZN3i22b

• https://x.com/AurelieRheumo/status/1983262445809311986/photo/1

Lung Ultrasound in CTD-ILD Prospective cohort 146 pts CTD-ILD 30 preclinical ILD 76 limited ILD 40 extensive ILD Median LUS scores higher if Extensive ILD LUS scores correlation w/ fibrosis severity, DLCO & FCV Agreement between LUS and HRCT severity 0.74 Excellent inter https://t.co/R9zGmCTT8Q

• https://x.com/AurelieRheumo/status/1983260820139098168/photo/1

Post-hoc analysis of CARE study comparing effect of Cenerimod 4mg vs. PBO Mos. 4-6: >10% improvement in alopecia w/Cenerimod Mos. 2-6: >10% improvement in mucosal ulcers w/ Cenerimod Early improvement in alopecia & ulcers w/Cenerimod Promising? #ACR25 @RheumNow Abs2440 https://t.co/mAqmIQashr

• https://x.com/RHEUMarampa/status/1983260232655536303/photo/1

#ACRBest @RheumNow https://t.co/SP3tib5tL1

• https://twitter.com/AurelieRheumo/status/1983256713324106093

52wks data of IZOKIPEB affibody IL17Ai RCT 2b/3 PsA Primary ACR 50 16wks Crossover 52 wks IZO 160 Q2W, IZO 160 QW, PBO-> IZO 160 QW ACR50 50% 57% 51% ACR70 36% 42% 42% PASI100 55% 64% 58% MDA 47% 52% 47% No specific enthesitis data presented No new safety signal Next https://t.co/J18rSTmyze

• https://x.com/AurelieRheumo/status/1983258996652851292/photo/1

#ACR25 Abstr#2601 At single cell level using CyTOF, metabolic activity varied btw HC & autoimmune groups but clusters in At-Risk ANA+ve appeared closer to #SLE. ANA+ve who progressed to AI-CTD showed Plasmablast expansion & enhanced glycolysis. Could be used as target @RheumNow https://t.co/jtrM1wvQLk

• https://x.com/Yuz6Yusof/status/1983253903673012604/photo/1

What's new in sjogren's? Promising phase III data of telitacicept (dual BLyS + APRIL neutralization) Pt in both dosing groups with decrease in ESSDAI compared to PBO but best results at higher (160mg) dose Similar rates of adverse events @RheumNow #ACR25 Abst LB11 https://t.co/r9JaVKzedH

• https://x.com/Dr_Brian_MD/status/1983251046290870387/photo/1

Gut microbiome on Urate metabolism study- 1500 men and women. From 3 cohorts- Framingham, nurses health and men's lifestyle with blood and stool data Focused on 5 urate metbolizing genes Abst#2590 #ACR25 @RheumNow https://t.co/YxBb3WfcbB

• https://x.com/bella_mehta/status/1983250427110904122/photo/1

RheumNow’s expanded coverage of the #ACR25 annual meeting is sponsored by Bristol Myers Squibb, Novartis, and UCB. All coverage content is selected by RheumNow and its faculty.

Is AI Smarter than a Doctor? Dr. Janet Pope reviews key takeaways from the session, "Artificial Intelligence in Medical Education: From Theory to Practice," at #ACR25. https://t.co/F6KEYAWi75 https://t.co/m57asdLGrn

• Is AI Smarter than a Doctor? | RheumNow